Science Corner 21 | Urolithin A: The Mitochondria Molecule Everyone’s Talking About

Spoiler alert: Next week, our latest SuppCo Tested report drops. And this time we are focused on Urolithin A, a compound generating significant excitement in the supplement and longevity research communities. Today, we will set the stage, exploring the science and why researchers believe it may be a promising tool for healthy aging.
Urolithin A (UA) is not something you find directly in foods. Instead, it is a metabolite produced when certain gut bacteria transform polyphenols from foods like pomegranates, walnuts, and berries. This indirect production means that not everyone can generate UA naturally, making supplementation an attractive option for those without the right microbiome composition.
At its core, UA has been studied for its role in mitophagy, the process by which cells identify and recycle damaged mitochondria. As we age, mitochondrial function declines, and the clean-up process becomes less efficient. By promoting mitophagy, UA may help preserve cellular energy production and reduce the accumulation of dysfunctional mitochondria.
A recent publication in Ageing Research Reviews provides a clear-eyed summary of the human evidence so far. While there is limited data on direct effects in human aging, trials have shown:
Mitochondrial activity and autophagy: Measurable increases in key biomarkers
Inflammation: Reductions in inflammatory markers by up to 30 percent in some trials
Muscle performance: Gains of 5-10 percent in strength or endurance measures
No changes in gut microbiota composition or broad physical function
One of the most important contributions to the UA literature is a 2022 randomized controlled trial on Mitopure, a patented UA formulation. Over four months, older adults supplementing with Mitopure showed roughly 12 percent greater leg strength, a 15 percent increase in VO₂ max, and notable improvements in mitochondrial protein expression in skeletal muscle. These results, while promising, still represent an early step. Like much of longevity research, the true question is whether these benefits persist or compound over years, not just months.
Quick Research Snapshot
Review (2024): Mitochondrial activity ↑, inflammation ↓ by ~30%, strength gains of 5–10%. No gut microbiota or broad function changes.
Mitopure RCT (2022): After 4 months, older adults saw ~12% improvement in leg muscle strength, ~15% higher VO₂ max, and significant mitochondrial biomarker increases.
Bottom line: Promising early results, but evidence is short-term and small-scale.
At SuppCo, our enthusiasm for emerging compounds like UA is matched by our commitment to evidence. Early data here is encouraging, but we temper excitement with the understanding that the longevity field is full of promising starts that do not always deliver in the long run. Still, UA’s unique mechanism and the quality of initial studies place it firmly on the “watch closely” list.
Next week, we will share the results of our independent testing on Urolithin A products so you can see which deliver what they promise.
--
Personal note from Jordan
I just started taking Urolithin A, and I am genuinely curious to see what happens. When something has a solid biological story and early studies that look promising, I like to try it for myself. For me, it goes down first thing in the morning as part of my supplement routine, right after the baby heads off to daycare. But I also know how easy it is to get swept up in the excitement. High-priced supplements with bold claims are everywhere, and not all of them live up to the hype. That is why we are testing UA products in next week’s SuppCo Tested release. If it truly delivers, it could be a real win for long-term health. For now, I will keep you posted on both my own experience and what the research tells us.
Citations from this article
Kuerec, Ajla Hodzic, et al. "Targeting aging with urolithin A in humans: A systematic review." Ageing Research Reviews 100 (2024). Link.
Singh, Anurag, et al. "Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults." Cell Reports Medicine 3.5 (2022). Link.